Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Axsome Therapeutics stock | $60.71
Learn how to easily invest in Axsome Therapeutics stock.
Axsome Therapeutics, Inc is a biotechnology business based in the US. Axsome Therapeutics shares (AXSM) are listed on the NASDAQ and all prices are listed in US Dollars. Axsome Therapeutics employs 70 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Axsome Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – AXSM – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Axsome Therapeutics stock price (NASDAQ: AXSM)Use our graph to track the performance of AXSM stocks over time.
Axsome Therapeutics shares at a glance
|Latest market close||$60.71|
|52-week range||$50.05 - $87.24|
|50-day moving average||$64.97|
|200-day moving average||$64.71|
|Wall St. target price||$140.21|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.37|
Buy Axsome Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Axsome Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Axsome Therapeutics price performance over time
|1 week (2021-07-18)||N/A|
|1 month (2021-06-29)||-12.85%|
|3 months (2021-04-29)||-1.73%|
|6 months (2021-01-25)||N/A|
|1 year (2020-07-25)||N/A|
|2 years (2019-07-25)||N/A|
|3 years (2018-07-25)||N/A|
|5 years (2016-07-25)||N/A|
Axsome Therapeutics financials
|Gross profit TTM||$0|
|Return on assets TTM||-32.37%|
|Return on equity TTM||-78.97%|
|Market capitalisation||$2.1 billion|
TTM: trailing 12 months
Shorting Axsome Therapeutics shares
There are currently 2.9 million Axsome Therapeutics shares held short by investors – that's known as Axsome Therapeutics's "short interest". This figure is 12.8% down from 3.3 million last month.
There are a few different ways that this level of interest in shorting Axsome Therapeutics shares can be evaluated.
Axsome Therapeutics's "short interest ratio" (SIR)
Axsome Therapeutics's "short interest ratio" (SIR) is the quantity of Axsome Therapeutics shares currently shorted divided by the average quantity of Axsome Therapeutics shares traded daily (recently around 356412.28501228). Axsome Therapeutics's SIR currently stands at 8.14. In other words for every 100,000 Axsome Therapeutics shares traded daily on the market, roughly 8140 shares are currently held short.
However Axsome Therapeutics's short interest can also be evaluated against the total number of Axsome Therapeutics shares, or, against the total number of tradable Axsome Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Axsome Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Axsome Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.0983% of the tradable shares (for every 100,000 tradable Axsome Therapeutics shares, roughly 98 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Axsome Therapeutics.
Find out more about how you can short Axsome Therapeutics stock.
Axsome Therapeutics share dividends
We're not expecting Axsome Therapeutics to pay a dividend over the next 12 months.
Axsome Therapeutics share price volatility
Over the last 12 months, Axsome Therapeutics's shares have ranged in value from as little as $50.05 up to $87.24. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Axsome Therapeutics's is 2.525. This would suggest that Axsome Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Axsome Therapeutics overview
Axsome Therapeutics, Inc. , a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Stocks similar to Axsome Therapeutics
Axsome Therapeutics in the news
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc. - AXSM
Were Hedge Funds Right About Dumping Axsome Therapeutics, Inc. (AXSM)?
Notable Monday Option Activity: AXSM, DFIN, MGM
Frequently asked questionsWhat percentage of Axsome Therapeutics is owned by insiders or institutions?
Currently 21.468% of Axsome Therapeutics shares are held by insiders and 62.778% by institutions. How many people work for Axsome Therapeutics?
Latest data suggests 70 work at Axsome Therapeutics. When does the fiscal year end for Axsome Therapeutics?
Axsome Therapeutics's fiscal year ends in December. Where is Axsome Therapeutics based?
Axsome Therapeutics's address is: 22 Cortlandt Street, New York, NY, United States, 10007 What is Axsome Therapeutics's ISIN number?
Axsome Therapeutics's international securities identification number is: US05464T1043 What is Axsome Therapeutics's CUSIP number?
Axsome Therapeutics's Committee on Uniform Securities Identification Procedures number is: 05464T104
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert